AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. have entered into a strategic alliance to research and develop applications for AXIM's patent covering water-soluble cannabinoids. The partnership centers on U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future patents, licensing, enforcement, and monetization proceeds, and claims for past infringement. Medical Marijuana, Inc. paid $600,000 for this assignment through a secured promissory note. Concurrently, the companies entered a consulting agreement where AXIM will provide research and development services focused on developing applications for the patent technology, with Medical Marijuana, Inc. paying AXIM $62,500 monthly for these services.
The technological breakthrough described in the patent involves molecular engineering that links cannabinoids to complementary compounds, creating polyfunctional cannabinoids that are more than 300 times more water-soluble than natural cannabinoids. This dramatically increased solubility enables significantly improved absorption and therapeutic delivery. The engineered constructs are designed to produce more potent responses than individual cannabinoid molecules, potentially allowing for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations.
Catalina Valencia, AXIM President, stated that the water solubility of CBD and other cannabinoids represents a significant development for improved administration and increased potency. She indicated the patent could result in developing a drug or treatment, most likely in sublingual form, able to treat various conditions including anxiety or seizures. Dr. Scott, MJNA Chairman and President, expressed confidence in AXIM's ability to provide R&D support for commercializing the patent technology, noting the potential for developing enhanced administration of water-soluble cannabinoids for certain ailments represents a major development for MJNA.
The consulting agreement has an initial non-cancellable term of one year expiring in January 2027, continuing month-to-month thereafter until terminated by either party with 90-day written notice. The alliance represents a significant development in cannabinoid research because traditional lipophilic cannabinoids have demonstrated limited bioavailability in many treatment applications. The technology offers expanded treatment potential where oil-based cannabinoids have been ineffective, including development of sublingual applications for anxiety and other indications. For more information about AXIM's diagnostic platform, visit https://www.aximbiotech.com.
This strategic alliance matters because it combines AXIM's patented water-soluble cannabinoid technology with Medical Marijuana, Inc.'s market knowledge and relationships in the cannabinoid arena. The collaboration could accelerate the development of more effective cannabinoid-based treatments with improved delivery mechanisms. The implications extend beyond the two companies to potentially impact patients suffering from conditions where traditional cannabinoid treatments have been limited by poor absorption. The technology's ability to enable lower therapeutic doses while maintaining efficacy could address safety concerns associated with higher cannabinoid concentrations, potentially expanding treatment options for neurological and psychological conditions.
